A review proposing how to classify harms linked to psychedelic use

The question

How should the problems and harms that can follow psychedelic use be described and classified? And can such problems be clearly attributed to the drug itself?

What they did

The authors wrote a review, not a new study. They drew on historical and current ways of classifying drug-related problems and organized possible complications of classic psychedelics such as psilocybin, LSD and 5-MeO-DMT. They used the typical timing of psychedelic effects as the organizing thread, separating acute effects, subacute effects in the days after, and longer-term effects. They also discussed where psychedelic-related disorders might fit within formal diagnostic systems.

What they found

The abstract reports no numbers, no participants and no statistical results. The authors argue that because psychedelics have low toxicity and little habit-forming potential, their risks are often overlooked by mental health professionals and under-assessed in research. They note that enthusiastic media coverage has contributed to more use outside clinical settings and a higher rate of psychedelic-related complications. They also point out that awareness of harms has historically emerged late for other psychoactive medicines, including opioids, cocaine and benzodiazepines, and they propose a classification framework as a starting point for assessing complications.

The fine print

This is a narrative review, so the authors chose which sources to discuss and there is no systematic search, no pooled data and no way to check the claims against a defined body of evidence. The abstract gives no figures on how common any complication is, and no evidence on how well the proposed classification works in practice. Statements about a rising rate of complications are asserted rather than quantified here. This summary is based on the abstract only.

What it means

The authors make the case that psychedelic research and practice need a clearer, shared language for describing things that go wrong, including effects that appear days or months later. It is a conceptual proposal rather than new evidence about how often harms occur.

Evidence grade: Very low. This is a narrative review that summarizes existing classification approaches and expert reasoning; it reports no new data, no participants and no pooled results.

This summary is based on the study’s published abstract.